DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of DBV Technologies (NASDAQ:DBVT) from a sell rating to a hold rating in a research note published on Saturday morning.

Several other analysts also recently issued reports on the company. JMP Securities reissued a “market outperform” rating and set a $21.00 target price on shares of DBV Technologies in a research note on Thursday, June 26th. HC Wainwright lifted their price objective on DBV Technologies from $7.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, May 5th. The Goldman Sachs Group raised DBV Technologies to a “sell” rating and set a $7.25 price objective on the stock in a research note on Thursday, May 29th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Tuesday, May 27th. Finally, Lifesci Capital raised DBV Technologies to a “strong-buy” rating in a research note on Thursday, June 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, DBV Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.75.

DBV Technologies Stock Up 12.0%

DBVT stock opened at $11.54 on Friday. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78. The stock has a market cap of $316.05 million, a P/E ratio of -2.35 and a beta of -0.59. The business’s 50-day moving average price is $9.42 and its 200-day moving average price is $6.55.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. The company had revenue of $0.51 million for the quarter. DBV Technologies had a negative net margin of 3,249.99% and a negative return on equity of 278.24%. On average, equities research analysts expect that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.